- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05471726
Verbesserung des antimikrobiellen Einsatzes nach der Entlassung
Verbesserung der antimikrobiellen Verwendung nach der Entlassung: eine multizentrische Stufenkeil-Versuchsstudie
One in five hospitalized patients is prescribed an antimicrobial at the time of discharge, and a large proportion of these post-discharge antimicrobials are unnecessary. The investigators will evaluate a novel method for reviewing post-discharge antimicrobial prescriptions in real-time with the goal of improving antimicrobial selection and duration.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Antimicrobial stewardship programs (ASPs) work to improve antibiotic prescribing within hospitals. ASPs often restrict their activities to inpatient antimicrobial-prescribing. However, at least 40% of all antimicrobial exposure associated with an acute-care hospital stay is prescribed at the time of hospital discharge (i.e., post-discharge). Post-discharge antimicrobials mediate clinical outcomes after discharge and may facilitate the spread of antimicrobial resistance.
Several studies have shown that post-discharge antimicrobial use is often inappropriate. For example, using national VA data, the investigators found that 61% of fluoroquinolone treatment days were prescribed at hospital discharge; manual chart reviews at 9 hospitals found that 40% of these post-discharge fluoroquinolone prescriptions were either unnecessary or sub-optimal. Other studies have found that 53-79% of all post-discharge antimicrobials are either unnecessary or sub-optimal.
Post-discharge antimicrobials are an important target for antimicrobial stewardship. However, inpatient stewardship metrics do not capture post-discharge antimicrobials and ASPs frequently do not evaluate these prescriptions. A 2016 VA survey found that less than 50% of hospitals routinely reviewed targeted antimicrobials at discharge. According to a 2016 survey in Michigan, only 17% of 48 hospitals had a process for reviewing outpatient antimicrobial orders at discharge.
It is unclear how inpatient stewardship resources can be effectively leveraged to improve post-discharge antimicrobial use. If the goal is to improve post-discharge antimicrobial use, a potentially effective strategy may be an audit-and-feedback process focused solely on prescriptions for patients who will soon be discharged. In this trial, the investigators will evaluate the feasibility and effectiveness of such a process.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Richard Roudebush VA Medical Center
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa Hospitals and Clinics
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201-1524
- Baltimore VA Medical Center
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Barnes Jewish Hospital and affiliated hospitals
-
-
Texas
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Audie L Murphy VA Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
--The local stewardship team agrees to implement the discharge stewardship intervention on at least one inpatient service or ward.
Exclusion Criteria:
--The hospital already has an audit-and-feedback process in place that focuses on antimicrobial prescribing at hospital discharge.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Prospective audit-and-feedback at discharge
When hospitals are in the intervention arm, they will perform the audit-and-feedback process focused on patients receiving antimicrobials who have an anticipated discharge. |
The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge. |
|
Kein Eingriff: Standard of care
When hospitals are in the control arm, they will not perform a stewardship process that focuses on hospital discharge. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Patients With Post-discharge Antibiotic Exposure
Zeitfenster: Antibiotics prescribed at the time of hospital discharge for the patient to take after discharge
|
Post-discharge antibiotic exposure captures the number of hospitalized patient who were discharged with an antibiotic to take after discharge. |
Antibiotics prescribed at the time of hospital discharge for the patient to take after discharge
|
|
Length of Post-discharge Antibiotic Therapy
Zeitfenster: Antibiotics prescribed at the point of hospital discharge
|
Duration in days of the post-discharge antibiotics that were prescribed |
Antibiotics prescribed at the point of hospital discharge
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Inpatient Antibiotic Length of Therapy
Zeitfenster: Every two-week period through study completion (48 weeks total)
|
Inpatient antibiotic LOT will be calculated by measuring inpatient LOT across all patients exposed to inpatient antibiotics on the participating services during the study period. |
Every two-week period through study completion (48 weeks total)
|
|
Percentage of Participants With Hospital Readmission
Zeitfenster: 30 days from discharge
|
Hospital readmissions reflect the need for (re) admission to an acute-care bed at a participating facility for any indication within 30 days of the patient's discharge. |
30 days from discharge
|
Mitarbeiter und Ermittler
Mitarbeiter
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IRB 202109288
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
All data will be aggregated to the hospital-level without including patient identifiers. This is a requirement for transmitting data across the institutions participating in this trial.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .